Evidence map›Paper›PMID 40010041›Full record

ArticleDrug and alcohol dependence2025

Buprenorphine adherence among a prospective cohort of homeless-experienced adults with opioid use disorder.

Danielle R Fine, Natalia Critchley, Katherine Hart, Susan Regan, Nora Sporn, Jessie Gaeta, Joe Wright, Gina Kruse, Travis P Baggett

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug and alcohol dependence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Danielle R FineMassachusetts General Hospital, 100 Cambridge Street, 16th Floor, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. Electronic address: drfine@mgh.harvard.edu.
Natalia CritchleyMassachusetts General Hospital, 100 Cambridge Street, 16th Floor, Boston, MA 02114, USA; Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Katherine HartMassachusetts General Hospital, 100 Cambridge Street, 16th Floor, Boston, MA 02114, USA.
Susan ReganMassachusetts General Hospital, 100 Cambridge Street, 16th Floor, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
Nora SpornMassachusetts General Hospital, 100 Cambridge Street, 16th Floor, Boston, MA 02114, USA.
Jessie GaetaBoston Health Care for the Homeless Program, 780 Albany Street, Boston, MA 02118, USA; Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA.
Joe WrightBoston Health Care for the Homeless Program, 780 Albany Street, Boston, MA 02118, USA.
Gina KruseMassachusetts General Hospital, 100 Cambridge Street, 16th Floor, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA; University of Colorado School of Medicine, 12631 E 17th Avenue, Aurora, CO 80045, USA.
Travis P BaggettMassachusetts General Hospital, 100 Cambridge Street, 16th Floor, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA; Boston Health Care for the Homeless Program, 780 Albany Street, Boston, MA 02118, USA.

Funding

Career Development Program in Substance Use and Addiction MedicineK12DA043490 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI A EDEN EVINS, NANCY A RIGOTTI · 2017 to 2026
$4.7M
Peer recovery support for people experiencing homelessness with opioid use disorderK23DA058200 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI Danielle Rebecca Fine · 2024 to 2026
$668k
NIDA NIH HHS K12 DA043490NIDA NIH HHS K23 DA058200
6 · The paper itself

Abstract

introductionPeople experiencing homelessness face high rates of opioid-related mortality. Buprenorphine is a medication that reduces opioid-related mortality, but adherence to this medication among people experiencing homelessness is not well-documented. This study assessed buprenorphine adherence and identified factors associated with it in this high-risk population.

methodsWe conducted a prospective cohort study of English- and Spanish-speaking adults (≥18 years) enrolled in the Boston Health Care for the Homeless Program outpatient-based opioid treatment (OBOT) program from 1/6/2022-1/5/2023. Our primary outcome was buprenorphine adherence, measured by the percentage of days covered (PDC). We used multivariable linear regression to identify demographics, social determinants, and clinical characteristics independently associated with buprenorphine adherence.

resultsOf 139 participants, 23 % were female, 45 % were non-Hispanic White, 37 % were Hispanic, 13 % were non-Hispanic Black, and the mean age was 42 years. The mean PDC was 49.4 % over the 4-month follow-up period. Older age (beta=7.03 % per decade; 95 % CI=1.99 %-12.08 %), living in a residential treatment facility at baseline (vs. being unhoused; beta=14.6 %; 95 % CI=1.7 %-27.6 %), higher levels of baseline recovery (beta=0.77 % per one-point increase in the recovery score; 95 % CI=0.21 %-1.32 %), a higher maximum buprenorphine dose (>16mg vs. ≤16mg; beta=13.1 %; 95 % CI=2.4 %-23.9 %), and receiving extended-release buprenorphine (beta=18.1 %; 95 % CI=4.3 %-31.9 %) were independently associated with a greater PDC.

conclusionsBuprenorphine adherence in this cohort of homeless-experienced adults was approximately 50 % over 4 months. Proactive up-titration of buprenorphine dosing, consideration of extended-release formulation, and ensured access to buprenorphine in residential treatment settings may improve adherence in this marginalized population.

Indexed as

BuprenorphineIll-Housed PersonsMedication AdherenceNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersAdultCohort StudiesFemaleHumansMaleMiddle AgedProspective StudiesBuprenorphineNarcotic AntagonistsBuprenorphineHomelessMedication adherenceOpioid use disorderOpioid use disorder treatmentVulnerable populations

Identifiers

PMID40010041
PMCPMC11959491

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.